Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762893 | 0.80 | KMT2A (0.56) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL2805013 | 0.80 | KDM4E (0.52) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL25399698 | 0.80 | MAPT (0.57) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL4678156 | 0.80 | KDM4E (0.52) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL14944881 | 0.78 | KDM4E (0.55) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL25401492 | 0.78 | MAPT (0.55) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL7299402 | 0.78 | KDM4E (0.56) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL12844407 | 0.77 | MAPT (0.48) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL12775851 | 0.76 | KDM4E (0.47) | KDM4EHSD17B10MAPTHIF1AALDH1A1 | |
| SCHEMBL13197096 | 0.76 | KDM4E (0.47) | KDM4EHSD17B10MAPTHIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945811-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-04-02 | — | — | US | disclosed |
| CN-117561247-A | Novel potassium channel inhibitors | 阿塞西翁制药公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4313973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2024-02-07 | — | — | EP | disclosed |
| US-20230406845-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-21 | — | — | US | disclosed |
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-111372928-B | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2022200162-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACECION PHARMA APS (DK) | 2022-09-29 | — | — | WO | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| CN-111372928-A | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3672953-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-07-01 | — | — | EP | disclosed |
| CN-111344281-A | Potassium channel inhibitors of substituted benzimidazoles | 阿塞西翁制药公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
| US-6376664-B1 | DETECTORS, CATALYST | THE OHIO STATE UNIVERSITY | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | KDM4E 1332/4885HSD17B10 1306/4885MAPT 3277/4885 |
| US-11945811-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KDM4E 1829/4885HSD17B10 1699/4885MAPT 1789/4885 |
| US-20230406845-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KDM4E 1291/4885HSD17B10 1632/4885MAPT 2025/4885 |
| US-11168074-B2 | Potassium channel inhibitors | KCNN2, KCNJ2, KCNN1 | KDM4E 1879/4885HSD17B10 1351/4885MAPT 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.